Optimization of Sedative Therapies Leads to Potential Pentobarbital Cost Avoidance in Treatment of Refractory Intracranial Hypertension

Ann Pharmacother. 2021 Feb;55(2):269-270. doi: 10.1177/1060028020945183. Epub 2020 Jul 29.

No abstract available

Publication types